Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Design
2.2. Sociodemographic and Anthropometric Data Collection
2.3. Laboratory Measurements
2.4. Statistical Analysis
3. Results
3.1. Characteristics of the Groups
3.2. Laboratory Evaluation
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Time, min | Acetonitrile, % | Methanol, % | 0.1% Formic Acid in Water, % |
---|---|---|---|
0 | 0 | 50 | 50 |
1.0 | 0 | 50 | 50 |
1.5 | 0 | 60 | 40 |
2.0 | 0 | 60 | 40 |
3.2 | 0 | 70 | 30 |
4.4 | 3 | 68 | 29 |
4.8 | 5 | 70 | 25 |
5.0 | 5 | 70 | 25 |
6.0 | 5 | 75 | 20 |
6.5 | 0 | 85 | 15 |
8.0 | 0 | 85 | 15 |
8.5 | 0 | 50 | 50 |
12 | 0 | 50 | 50 |
Analyte | Transition Type | Q1 | Q3 | tR, min | CE, V | DP, V | CXP, V |
---|---|---|---|---|---|---|---|
1,25(OH)2D3 | quantifier | 399.3 | 135.1 | 5.0 | 28 | 89 | 16 |
qualifier | 399.3 | 381.3 | 19 | 89 | 14 | ||
24,25(OH)2D3 | quantifier | 417.3 | 399.3 | 4.8 | 13 | 66 | 15 |
qualifier | 417.3 | 381.3 | 15 | 66 | 14 | ||
25(OH)D3 | quantifier | 401.3 | 383.3 | 6.1 | 13 | 59 | 15 |
qualifier | 401.3 | 365.4 | 17 | 59 | 13 | ||
3-epi-25(OH)D3 | quantifier | 401.29 | 383.2 | 6.3 | 14 | 110 | 9 |
qualifier | 401.29 | 365.3 | 17 | 110 | 9 | ||
25(OH)D2 | quantifier | 413.3 | 355.3 | 6.3 | 15 | 110 | 7 |
qualifier | 413.3 | 395.3 | 13 | 110 | 7 | ||
1,25(OH)2D3-d6 | IS | 405.3 | 135.0 | 5 | 30 | 170 | 12 |
24,25(OH)2D3-d6 | IS | 423.3 | 387.5 | 4.8 | 16 | 150 | 7 |
25(OH)D3-d6 | IS | 407.4 | 389.3 | 6.1 | 12 | 120 | 11 |
3-epi-25(OH)D3-d3 | IS | 404.4 | 368.3 | 6.3 | 18 | 150 | 6 |
References
- Mannstadt, M.; Bilezikian, J.P.; Thakker, R.V.; Hannan, F.M.; Clarke, B.L.; Rejnmark, L.; Mitchell, D.M.; Vokes, T.J.; Winer, K.K.; Shoback, D.M. Hypoparathyroidism. Nat. Rev. Dis. Prim. 2007, 3, 17055. [Google Scholar] [CrossRef] [PubMed]
- Brandi, M.L.; Bilezikian, J.P.; Shoback, D.; Bouillon, R.; Clarke, B.L.; Thakker, R.V.; Khan, A.A.; Potts, J.T., Jr. Management of hypoparathyroidism: Summary statement and guidelines. J. Clin. Endocrinol. Metab. 2016, 101, 2273–2283. [Google Scholar] [CrossRef] [PubMed]
- Bikle, D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 2014, 21, 319–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saponaro, F.; Saba, A.; Zucchi, R. An update on vitamin D metabolism. Int. J. Mol. Sci. 2020, 21, 6573. [Google Scholar] [CrossRef]
- Jones, G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu. Rev. Nutr. 2013, 33, 23–44. [Google Scholar] [CrossRef] [PubMed]
- Dusso, A.; Lopez-Hilker, S.; Rapp, N.; Slatopolsky, E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988, 34, 368–375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dusso, A.S.; Finch, J.; Brown, A.; Ritter, C.; Delmez, J.; Schreiner, G.; Slatopolsky, E. Extrarenal production of calcitriol in normal and uremic humans. J. Clin. Endocrinol. Metab. 1991, 72, 157–164. [Google Scholar] [CrossRef]
- Lensmeyer, G.; Poquette, M.; Wiebe, D.; Binkley, N. The C-3 epimer of 25-hydroxyvitamin D3 is present in adult serum. J. Clin. Endocrinol. Metab. 2012, 97, 163–168. [Google Scholar] [CrossRef] [Green Version]
- Al-Zohily, B.; Al-Menhali, A.; Gariballa, S.; Haq, A.; Shah, I. Epimers of vitamin D: A review. Int. J. Mol. Sci. 2020, 21, 470. [Google Scholar] [CrossRef] [Green Version]
- Kooh, S.W.; Fraser, D.; DeLuca, H.F.; Holick, M.F.; Belsey, R.E.; Clark, M.B.; Murray, T.M. Treatment of hypoparathyroidism and pseudo hypoparathyroidism with metabolites of vitamin D: Evidence for impaired conversion of 25-hydroxyvitamin D to 1α, 25-dihydroxyvitamin D. N. Engl. J. Med. 1975, 293, 840–844. [Google Scholar] [CrossRef]
- Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281. [Google Scholar] [CrossRef] [PubMed]
- Lund, B.; Sorensen, O.H.; Lund, B.I.; Bishop, J.E.; Norman, A.W. Vitamin D metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 1980, 51, 606–610. [Google Scholar] [CrossRef] [PubMed]
- Bilezikian, J.P.; Brandi, M.L.; Cusano, N.E.; Mannstadt, M.; Rejnmark, L.; Rizzoli, R.; Rubin, M.R.; Winer, K.K.; Liberman, U.A.; Potts, J.T., Jr. Management of hypoparathyroidism: Present and future. J. Clin. Endocrinol. Metab. 2016, 101, 2313–2324. [Google Scholar] [CrossRef] [PubMed]
- Kovaleva, E.V.; Eremkina, A.K.; Krupinova, Y.A.; Mirnaya, S.S.; Kim, I.V.; Kuznetzov, N.S.; Andreeva, E.N.; Karonova, T.L.; Kryukova, I.V.; Mudunov, A.M.; et al. Review of clinical practice guidelines for hypoparathyroidism. Probl. Endocrinol. 2021, 67, 68–83. [Google Scholar] [CrossRef]
- Thode, J.; Juul-Jørgensen, B.; Bhatia, H.M.; Kjaerulf-Nielsen, M.; Bartels, P.D.; Fogh-Andersen, N.; Siggaard-Andersen, O. Comparison of serum total calcium, albumin-corrected total calcium, and ionized calcium in 1213 patients with suspected calcium disorders. Scand. J. Clin. Lab. Investig. 1989, 49, 217–223. [Google Scholar]
- Povaliaeva, A.; Pigarova, E.; Zhukov, A.; Bogdanov, V.; Dzeranova, L.; Mel’Nikova, O.; Pekareva, E.; Malysheva, N.; Ioutsi, V.; Nikankina, L.; et al. Evaluation of vitamin D metabolism in patients with type 1 diabetes mellitus in the setting of cholecalciferol treatment. Nutrients 2020, 12, 3873. [Google Scholar] [CrossRef]
- Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [Google Scholar] [CrossRef] [Green Version]
- Pigarova, E.A.; Rozhinskaya, L.Y.; Belaya, Z.E.; Dzeranova, L.K.; Karonova, T.L.; Ilyin, A.V.; Mel’nichenko, G.A.; Dedov, I.I. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Probl. Endokrinol. 2016, 62, 60–84. [Google Scholar] [CrossRef]
- Dirks, N.F.; Martens, F.; Vanderschueren, D.; Billen, J.; Pauwels, S.; Ackermans, M.T.; Endert, E.; den Heijer, M.; Blankenstein, M.A.; Heijboer, A.C. Determination of human reference values for serum total 1,25-dihydroxyvitamin D using an extensively validated 2D ID-UPLC–MS/MS method. J. Steroid Biochem. Mol. Biol. 2016, 164, 127–133. [Google Scholar] [CrossRef]
- Tang, J.C.Y.; Nicholls, H.; Piec, I.; Washbourne, C.J.; Dutton, J.J.; Jackson, S.; Greeves, J.; Fraser, W.D. Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC–MS/MS method. J. Nutr. Biochem. 2017, 46, 21–29. [Google Scholar] [CrossRef] [Green Version]
- Gronskaia, S.; Melnichenko, G.; Rozhinskaya, L.; Grebennikova, T.; Mamedova, E.; Pigarova, E.; Przhialkovskaya, E.; Dzeranova, L.; Dedov, I.; Fadeyev, V.; et al. A registry for patients with chronic hypoparathyroidism in Russian adults. Endocr. Connect. 2020, 9, 627–636. [Google Scholar] [CrossRef] [PubMed]
- Kovaleva, E.V.; Eremkina, A.K.; Elfimova, A.R.; Krupinova, J.A.; Bibik, E.E.; Maganeva, I.S.; Gorbacheva, A.M.; Dobreva, E.A.; Melnichenko, G.A.; Mokrysheva, N.G. The Russian Registry of Chronic Hypoparathyroidism. Front. Endocrinol. 2022, 13, 800119. [Google Scholar] [CrossRef] [PubMed]
- Saha, S.; Sreenivas, V.; Goswami, R. Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 2021, 106, 2092–2102. [Google Scholar] [CrossRef] [PubMed]
- Clarke, B.L.; Vokes, T.J.; Bilezikian, J.P.; Shoback, D.M.; Lagast, H.; Mannstadt, M. Effects of parathyroid hormone rhPTH (1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine 2017, 55, 273–282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bollerslev, J.; Rejnmark, L.; Marcocci, C.; Shoback, D.M.; Sitges-Serra, A.; van Biesen, W.; Dekkers, O.M. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 2015, 173, G1–G20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- García-Pascual, L.; Barahona, M.J.; Perea, V.; Simó, R. Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism. J. Clin. Endocrinol. Metab. 2017, 102, 259–266. [Google Scholar] [CrossRef]
- Zittermann, A.; Ernst, J.B.; Becker, T.; Dreier, J.; Knabbe, C.; Gummert, J.F.; Kuhn, J. Measurement of Circulating 1,25-Dihydroxyvitamin D: Comparison of an Automated Method with a Liquid Chromatography Tandem Mass Spectrometry Method. Int. J. Anal. Chem. 2016, 2016, 8501435. [Google Scholar] [CrossRef]
HypoPT | Control (n = 38) | p * | |||
---|---|---|---|---|---|
Total (n = 38) | c-HypoPT (n = 13) | nc-HypoPT (n = 25) | |||
Age, years | 49.6 (38.0; 60.0) | 53.0 (45.6; 57.9) | 46.1 (37.6; 60.8) | 48.8 (39.9; 55.5) | p1–4 = 0.578 p2–3 = 0.644 |
Sex (woman, %) | 89.5 | 92.3 | 88 | 78.9 | p1–4 = 0.346 p2–3 = 1.000 |
BMI, kg/m2 | 27.1 (24.3; 31.6) | 28.6 (23.6; 32.2) | 27.0 (24.4; 31.4) | 25.2 (23.1; 28.4) | p1–4 = 0.113 p2–3 = 0.644 |
c-HypoPT (n = 13) | nc-HypoPT (n = 25) | p | |
---|---|---|---|
Duration of HypoPT, months | 61.0 (35.0; 83.0) | 62.0 (19.0; 98.0) | 0.794 |
Received Therapy Alfacalcidol, mcg/per day Calcium, mg/per day Cholecalciferol, IU/per day | 2.0 (1.0; 2.25) 2000 (1500; 3000) 2000 (2000; 2500) | 1.5 (1.0; 2.0) 2000 (1500; 3000) 1200 (0; 2100) | 0.306 0.575 0.060 |
Laboratory Parameter | Total HypoPT (n = 38) | Control (n = 38) | p | Reference Range |
---|---|---|---|---|
Total calcium, mmol/L | 2.10 (1.93; 2.25) | 2.36 (2.31; 2.43) | * <0.001 | 2.15–2.55 |
Albumin-adjusted calcium, mmol/L | 2.01 (1.85; 2.15) | 2.25 (2.21; 2.31) | * <0.001 | 2.15–2.55 |
Phosphorus, mmol/L | 1.54 (1.41; 1.76) | 1.18 (1.06; 1.23) | * <0.001 | 0.74–1.52 |
PTH, pg/mL | 5.8 (4.3; 9.3) (n = 29) | 38.4 (34.9; 42.1) | * <0.001 | 15–65 |
Creatinine, µmol/L | 77.2 (72.6; 87.0) | 71.5 (65.7; 81.8) | * 0.041 | 63–110 (male) 50–98 (female) |
Albumin, g/L | 44.8 (42.3; 46.3) | 45.0 (44.1; 46.7) | 0.188 | 35–50 |
Magnesium, mmol/L | 0.75 (0.71; 0.80) | 0.81 (0.78; 0.85) | * <0.001 | 0.7–1.05 |
25(OH)D3, ng/mL | 35.3 (29.6; 42.0) | 25.1 (17.9; 31.3) | * <0.001 | >30 1 |
3-epi-25(OH)D3, ng/mL | 3.3 (2.5; 4.5) | 2.1 (1.4; 2.6) | * <0.001 | Not available |
1,25(OH)2D3, pg/mL | 71 (47; 96) | 40 (34; 59) | * <0.001 | 25–66 2 |
24,25(OH)2D3, ng/mL | 3.8 (3.0; 5.1) | 1.9 (1.3; 2.7) | * <0.001 | 0.5–5.6 2 |
25(OH)D3/24,25(OH)2D3 | 8.9 (7.6; 11.1) | 13.5 (11.1; 17.0) | * <0.001 | 7–23 2 |
Laboratory Parameter | c-HypoPT (n = 13) | nc-HypoPT (n = 25) | p | Reference Range |
---|---|---|---|---|
Total calcium, mmol/L | 2.26 (2.25; 2.32) | 2.01 (1.85; 2.10) | * <0.001 | 2.15–2.55 |
Albumin-adjusted calcium, mmol/L | 2.18 (2.15; 2.26) | 1.93 (1.79; 2.00) | * <0.001 | 2.15–2.55 |
Phosphorus, mmol/L | 1.51 (1.31; 1.64) | 1.58 (1.44; 1.90) | 0.113 | 0.74–1.52 |
PTH, pg/mL | 6.7 (5.6; 8.6) (n = 11) | 5.3 (3.9; 9.9) (n = 18) | 0.256 | 15–65 |
Creatinine, µmol/L | 90.2 (81.1; 97.3) | 74.2 (69.1; 81.8) | * 0.002 | 63–110 (male) 50–98 (female) |
Albumin, g/L | 45.0 (43.0; 46.7) | 44.0 (42.2; 45.6) | 0.363 | 35–50 |
Magnesium, mmol/L | 0.79 (0.74; 0.84) | 0.74 (0.68; 0.78) | * 0.032 | 0.7–1.05 |
25(OH)D3, ng/mL | 38.7 (29.8; 45.6) | 34.8 (28.6; 40.6) | 0.518 | >30 1 |
3-epi-25(OH)D3, ng/mL | 3.3 (3.0; 5.3) | 3.1 (2.3; 3.9) | 0.103 | Not available |
1,25(OH)2D3, pg/mL | 95 (59; 96) | 60 (45; 92) | 0.234 | 25–66 2 |
24,25(OH)2D3, ng/mL | 4.4 (3.1; 5.2) | 3.7 (2.9; 4.8) | 0.329 | 0.5–5.6 2 |
25(OH)D3/24,25(OH)2D3 | 8.7 (6.9; 10.8) | 9.6 (8.0; 11.1) | 0.523 | 7–23 2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhukov, A.; Povaliaeva, A.; Abilov, Z.; Kovaleva, E.; Usoltseva, L.; Eremkina, A.; Ioutsi, V.; Dzeranova, L.; Pigarova, E.; Rozhinskaya, L.; et al. Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism. Metabolites 2022, 12, 1279. https://doi.org/10.3390/metabo12121279
Zhukov A, Povaliaeva A, Abilov Z, Kovaleva E, Usoltseva L, Eremkina A, Ioutsi V, Dzeranova L, Pigarova E, Rozhinskaya L, et al. Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism. Metabolites. 2022; 12(12):1279. https://doi.org/10.3390/metabo12121279
Chicago/Turabian StyleZhukov, Artem, Alexandra Povaliaeva, Zaur Abilov, Elena Kovaleva, Liliya Usoltseva, Anna Eremkina, Vitaliy Ioutsi, Larisa Dzeranova, Ekaterina Pigarova, Liudmila Rozhinskaya, and et al. 2022. "Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism" Metabolites 12, no. 12: 1279. https://doi.org/10.3390/metabo12121279
APA StyleZhukov, A., Povaliaeva, A., Abilov, Z., Kovaleva, E., Usoltseva, L., Eremkina, A., Ioutsi, V., Dzeranova, L., Pigarova, E., Rozhinskaya, L., & Mokrysheva, N. (2022). Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism. Metabolites, 12(12), 1279. https://doi.org/10.3390/metabo12121279